Ohsaki Y, Gross A J, Le P T, Oie H, Johnson B E
NCI-Navy Medical Oncology Branch, National Cancer Institute, National Institutes of Health, National Naval Medical Center, Bethesda, MD, USA.
Oncology. 1999;56(2):155-9. doi: 10.1159/000011957.
The tumoral production of brain natriuretic peptide (BNP) was studied using 9 small cell lung cancer (SCLC) cell lines which were established from patients with small cell lung cancer. BNP cDNA fragment was generated from 20 microg total RNA which was prepared from the human right cardiac atrium by reverse transcription-based polymerase chain reaction. Expression of BNP mRNA was detected in 30 microg total cellular RNA from these cell lines by RNase protection assays in 5 of 9 SCLC cell lines. Radioimmunoassays using 125I-radiolabeled human BNP(1-32) and antihuman BNP(1-32) antibody detected immunoreactivity in cell pellets from SCLC cell lines which had detectable BNP mRNA. BNP immunoreactivity in the cell pellets corresponds with the data from BNP mRNA analyses. We conclude that SCLC cells have detectable BNP mRNA by RNase protection assay and BNP immunoreactivity in the cells.
利用从小细胞肺癌患者身上建立的9个小细胞肺癌（SCLC）细胞系，研究了脑钠肽（BNP）的肿瘤产生情况。BNP cDNA片段是由20微克总RNA产生的，该总RNA是通过基于逆转录的聚合酶链反应从人右心房制备的。通过核糖核酸酶保护分析，在9个SCLC细胞系中的5个细胞系的30微克总细胞RNA中检测到BNP mRNA的表达。使用125I放射性标记的人BNP(1-32)和抗人BNP(1-32)抗体的放射免疫分析在具有可检测BNP mRNA的SCLC细胞系的细胞沉淀中检测到免疫反应性。细胞沉淀中的BNP免疫反应性与BNP mRNA分析的数据一致。我们得出结论，通过核糖核酸酶保护分析可在SCLC细胞中检测到BNP mRNA，并且细胞中存在BNP免疫反应性。
